Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2017-002093-40-NL
EUCTR2017-002093-40-NL
Active, not recruiting
Phase 1

68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma - PSMA-PET imaging for advanced ACC/SDC

Radboudumc0 sites25 target enrollmentJune 8, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Radboudumc
Enrollment
25
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 8, 2017
End Date
May 14, 2018
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Radboudumc

Eligibility Criteria

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • •locally advanced, recurrent or metastatic ACC/SDC
  • •Age \= 18 years old
  • •Ability to provide written informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 15
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 10

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • •Contra\-indication for PET imaging (pregnancy, breast feeding, severe claustrophobia)
  • •Impaired renal function: MDRD \<30 ml/min/1,73 m2
  • •Impaired liver function: AST and ALT \= 2\.5 x ULN (\=5 x ULN for patients with liver metastases)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma
NL-OMON44299Radboud Universitair Medisch Centrum25
Active, not recruiting
Phase 1
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumorsadvanced/metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code 10027477Term: Metastatic carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-004376-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS400
Recruiting
Phase 2
PETCT and MRI guided boost for prostate cancer radiotherapyHealth Condition 1: C61- Malignant neoplasm of prostate
CTRI/2022/09/045258Varian Medical System
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2016-000842-79-BEInstitut Jules Bordet75
Active, not recruiting
Phase 1
Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.Sarcoidosis.Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2016-002160-14-NLSt. Antonius Hospital